CROs DaVita Clinical Research, HealthCare Partners Clinical Research to merge

By Zachary Brennan

- Last updated on GMT

CROs DaVita Clinical Research, HealthCare Partners to merge

Related tags Davita clinical research Chronic kidney disease

CROs are consolidating further, this time with DaVita HealthCare Partners’ business units DaVita Clinical Research (DCR) and HealthCare Partners Clinical Research merging to further expand their services, specifically for patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).

The merger allows the two CROs to offer data analytics capabilities on de-identified data of about one million active patients receiving care at DaVita HealthCare Partners’ centers, including 170,000 US dialysis patients receiving care from DaVita Kidney Care and 836,000 multi-specialty patients receiving care from HealthCare Partners. Terms of the merger were not disclosed and no employees will be laid off.

We see great synergy in the joining of these...The best way to capture the value in the combination of these groups is to let them come together naturally. The support to join the teams comes from the teammates themselves​,” Amy Young, VP and general manager for DaVita Clinical Research, told “Both groups did late phase research, but not in ways that are duplicative. Our combined clinical trials capability now has a broad reach both geographically and therapeutically. Our HEOR [health economics and outcomes research] capability has always been strong in the area of chronic disease epidemiology. We now have tremendous data access and insights to add to that already strong scientific capability​.”  

Young added that since 1997, DaVita has been a leader in kidney-related trials, epidemiology and data analytics.

"HealthCare Partners' extensive patient database is diverse and reflects real-world evidence in an integrated care organization​," said Riya Pulicharam, medical director of late phase research and clinical outcomes at HealthCare Partners Clinical Research. "We have conducted clinical trials across multiple therapeutic areas for more than 10 years, and combining our clinical research and data analytics capabilities with DCR greatly enhances our ability to meet additional clients' needs​."

The combined entity's capabilities include claims, pharmacy and electronic health record data analysis. The combined organization's assets will help boost research-study enrollment and retention, offer access to nearly a million primary care and multi-specialty patients, as well as 280,000 CKD and ESRD patients.

The merger will also build on the intellectual, financial and human resources necessary to support the analysis of burden-of-illness studies to budget impact models to market-sizing assessments.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us


View more